ArticleAntimicrobial agents and chemotherapy2019
Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Defining the Mechanism of Action and Resistance of NewACS chemical biology · 2026Article
- Protective mechanism of action of the antifungal drug naftifine againstAntimicrobial agents and chemotherapy · 2026Article
- A two-step screen identifies a small molecule that disrupts membrane voltage and is effective against growing and persister gram-negative bacteria.Microbiology spectrum · 2026Article
- Thienopyrimidine amide analogs target MmpL3 inAntimicrobial agents and chemotherapy · 2025Article
- Mutations in Genes with a Role in Cell Envelope Biosynthesis Render Gram-Negative Bacteria Highly Susceptible to the Anti-Infective Small Molecule D66.Microorganisms · 2025Article
- Defining the mechanism of action of the nitrofuranyl piperazine HC2210 against Mycobacterium abscessus.npj antimicrobials and resistance · 2025Article
- Investigating the unbinding mechanisms and kinetics of MmpL3 inhibitors: A computational study.Protein science : a publication of the Protein Society · 2025Article
- Tailored phenyl ureas eradicate drug-resistantChemical science · 2025Article
- Genetic and Cheminformatic Characterization ofACS infectious diseases · 2025Article
- Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Developing novel indoles as antitubercular agents and simulated annealing-based analysis of their binding with MmpL3.Future medicinal chemistry · 2025Article
- Structural modeling and characterization of the Mycobacterium tuberculosis MmpL3 C-terminal domain.FEBS letters · 2024Article
- Computational drug repositioning identifies niclosamide and tribromsalan as inhibitors of Mycobacterium tuberculosis and Mycobacterium abscessus.Tuberculosis (Edinburgh, Scotland) · 2024Article
- Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action andAntimicrobial agents and chemotherapy · 2023Article
- Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections.Expert opinion on drug discovery · 2023Review
- Identification and structure-activity relationships for a series of N, N-disubstituted 2-aminobenzothiazoles as potent inhibitors of S. aureus.Bioorganic & medicinal chemistry letters · 2023Article
- Molecular Mechanisms of MmpL3 Function and Inhibition.Microbial drug resistance (Larchmont, N.Y.) · 2023Review
- The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development.Molecular biomedicine · 2022Review
- Article
- A Hydrazine-Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
John T WilliamsDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.ORCID 0000-0002-2742-1636
Elizabeth R HaidererDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Garry B CoulsonDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Kayla N ConnerDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Edmund EllsworthDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA.
Chao ChenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Nadine Alvarez-CabreraCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Wei LiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-9604-9452
Robert B AbramovitchDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA abramov5@msu.edu.ORCID 0000-0002-4119-4169
Michigan State University · USHackensack Meridian Health · USColorado State University · US
Funding
Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI MISSIAKAS, DOMINIQUE M. · 2003 to 2013
$87.6MDiscovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0MMmpL3 as a target for novel anti-TB agentsR01AI116525 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2015 to 2024
$5.3MMechanisms of Mycobacterium Tuberculosis pH-driven AdaptationR01AI116605 · NIAID · MICHIGAN STATE UNIVERSITY · PI ABRAMOVITCH, ROBERT B · 2016 to 2020
$1.9MNon-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosisR21AI117018 · NIAID · MICHIGAN STATE UNIVERSITY · PI ABRAMOVITCH, ROBERT B, TEPE, JETZE J. · 2016 to 2017
$400kNIAID NIH HHS R01 AI116525NIAID NIH HHS R01 AI116605NIAID NIH HHS R01 AI132374NIAID NIH HHS R21 AI117018NIAID NIH HHS U54 AI057153
Abstract
The
Indexed as
Antitubercular AgentsBacterial ProteinsBenzamidesBenzothiazolesBinding SitesBiological TransportCord FactorsDrug Resistance, BacterialGalactansGene ExpressionHigh-Throughput Screening AssaysMembrane Transport ProteinsMicrobial Sensitivity TestsModels, MolecularMutationMycobacterium abscessusAntitubercular AgentsarabinogalactanBacterial ProteinsBenzamidesBenzothiazolesCord FactorsGalactansMembrane Transport ProteinsMmpL3 protein, Mycobacterium tuberculosisMycolic AcidsPyridinesRecombinant Proteinstrehalose monomycolateantimicrobialscell envelopemechanisms of resistanceMycobacterium tuberculosisphenotypic screening
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.